Rocket Pharmaceuticals (RCKT) PT Raised to $15 at Cantor Fitzgerald
May 8, 2026 8:07 AM
Cantor Fitzgerald analyst Josh Schimmer raised the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $15.00 (from $10.00) while maintaining a Overweight rating.
